全文获取类型
收费全文 | 2271篇 |
免费 | 160篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 67篇 |
妇产科学 | 69篇 |
基础医学 | 351篇 |
口腔科学 | 34篇 |
临床医学 | 206篇 |
内科学 | 475篇 |
皮肤病学 | 105篇 |
神经病学 | 284篇 |
特种医学 | 77篇 |
外科学 | 210篇 |
综合类 | 10篇 |
预防医学 | 141篇 |
眼科学 | 30篇 |
药学 | 145篇 |
中国医学 | 8篇 |
肿瘤学 | 218篇 |
出版年
2024年 | 2篇 |
2023年 | 24篇 |
2022年 | 48篇 |
2021年 | 90篇 |
2020年 | 69篇 |
2019年 | 78篇 |
2018年 | 89篇 |
2017年 | 78篇 |
2016年 | 94篇 |
2015年 | 91篇 |
2014年 | 116篇 |
2013年 | 135篇 |
2012年 | 207篇 |
2011年 | 212篇 |
2010年 | 119篇 |
2009年 | 104篇 |
2008年 | 164篇 |
2007年 | 128篇 |
2006年 | 118篇 |
2005年 | 126篇 |
2004年 | 93篇 |
2003年 | 83篇 |
2002年 | 67篇 |
2001年 | 15篇 |
2000年 | 8篇 |
1999年 | 7篇 |
1998年 | 9篇 |
1997年 | 8篇 |
1996年 | 8篇 |
1995年 | 5篇 |
1994年 | 3篇 |
1993年 | 3篇 |
1992年 | 2篇 |
1990年 | 4篇 |
1989年 | 6篇 |
1988年 | 2篇 |
1986年 | 3篇 |
1985年 | 3篇 |
1983年 | 2篇 |
1981年 | 4篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1975年 | 1篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1967年 | 1篇 |
1960年 | 1篇 |
1957年 | 1篇 |
1955年 | 1篇 |
1934年 | 1篇 |
排序方式: 共有2445条查询结果,搜索用时 109 毫秒
11.
Ricci V Filocamo M Regis S Corsolini F Stroppiano M Di Duca M Gatti R 《American journal of medical genetics. Part A》2003,(1):84-87
Hunter syndrome (Mucopolysaccharidosis type II) is a rare X-linked recessive lysosomal storage disorder caused by the deficiency of the enzyme iduronate-2-sulfatase (IDS). To date, more than 200 different mutations have been reported in the IDS gene, located on Xq27.3-q28. Here, we report two new mutations (M488I and G489A) identified in hemizygosity in an Italian Hunter patient. Their "in vitro" expression by COS 7 cells was carried out in order to evaluate their functional consequence on enzyme activity as well as their possible cumulative effect on the malfunctioning of the protein. The results obtained enabled us to confirm the G489A mutation as causative. The M488I mutation, however, could not be unequivocally considered as causing disease because of its residual activity. Although a cumulative effect of the two mutations can be excluded "in vitro," we are cautious about drawing a conclusion with regard to the possible role that the two mutations could have played "in vivo" in modulating the phenotype of the patient. Finally, the knowledge of the molecular defect of the patient has enabled us to identify the carriers, providing reliable genetic counselling to the females of the family. 相似文献
12.
Doriana Misceo Mario Ventura Verena Eder Mariano Rocchi Nicoletta Archidiacono 《Chromosome research》2003,11(4):323-326
A study was made of the organization of the chromosome orthologous to HSA16 in primates using a panel of 8 BAC probes spanning human chromosome 16. The probes were used in FISH experiments on great apes and on representatives of the Old World monkeys, New World monkeys, and lemurs. The domestic cat was used as an outgroup. The results indicate that 16p and 16q were separate chromosomes in a primate ancestor. They fused in a Catarrhini ancestor giving rise to the present day form found in HSA, great apes, and Old World monkeys. Several rearrangements were found in New World monkeys. 相似文献
13.
14.
Differences in maintenance of CD8+ and CD4+ bacteria-specific effector-memory T cell populations 总被引:1,自引:0,他引:1
Schiemann M Busch V Linkemann K Huster KM Busch DH 《European journal of immunology》2003,33(10):2875-2885
Our knowledge about the kinetics and dynamics of complex pathogen-specific CD8(+) T cell responses and the in vivo development of CD8(+) memory T cells has increased substantially over the past years; in comparison, relatively little is known about the CD4(+) T cell compartment. We monitored and directly compared the phenotypical changes of pathogen (Listeria monocytogenes)-specific CD8(+) and CD4(+) T cell responses under conditions leading to effective and long-lasting protective immunity. We found that the general kinetics of bacteria-specific CD8(+) and CD4(+) T cells during the effector and post-effector phases are synchronized. However, later during the memory phase, CD8(+) and CD4(+) T cell populations differ substantially. Whereas CD8(+) memory T cell populations with immediate effector function are readily detectable in lymphoid and non-lymphoid tissues and remain remarkably stable in size, antigen-specific CD4(+) effector-memory T cells decline continuously in frequency over time. These findings have important implications for the better understanding of the in vivo development of protective immunity towards intracellular pathogens. 相似文献
15.
Tudor Kate Maloney Shannon Raja Anam Baer Ruth Blakemore Sarah-Jayne Byford Sarah Crane Catherine Dalgleish Tim De Wilde Katherine Ford Tamsin Greenberg Mark Hinze Verena Lord Liz Radley Lucy Opaleye Emerita Satiro Taylor Laura Ukoumunne Obioha C. Viner Russell Kuyken Willem Montero-Marin Jesus 《Prevention science》2022,23(6):934-953
Prevention Science - There is evidence that universal school-based mindfulness training (SBMT) can have positive effects for young people. However, it is unknown who benefits most from such... 相似文献
16.
Gretl Hendrickx Verena Fischer Astrid Liedert Simon von Kroge Melanie Haffner-Luntzer Laura Brylka Eva Pawlus Michaela Schweizer Timur Yorgan Anke Baranowsky Tim Rolvien Mona Neven Udo Schumacher David J Beech Michael Amling Anita Ignatius Thorsten Schinke 《Journal of bone and mineral research》2021,36(2):369-384
17.
Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates. 总被引:2,自引:0,他引:2
Pawel Surowiak Verena Materna Malgorzata Drag-Zalesinska Andrzej Wojnar Irina Kaplenko Marek Spaczyński Manfred Dietel Maciej Zabel Hermann Lage 《International journal of gynecological pathology》2006,25(2):131-139
High cytoplasmic expression of maspin was described in ovarian cancers of shorter survival rates. Until now, no relationship has been described between expression of maspin and sensitivity to cisplatin in ovarian cancers. This study aimed at examining the relationship between expression of maspin, detected by immunohistochemistry and clinical response to cisplatin in ovarian cancer cases as well as the in vitro sensitivity to cisplatin of 11 ovarian cancer cell lines. The analyzes were performed on 73 samples of ovarian cancer and on A2780P, A2780RCIS, CAOV-3, EFO 21, EFO 27, ES-2, Mdah 2774, OAW 42, OVCAR-3, PA-1, and SKOV-3 ovarian cancer cells. Cytoplasmic maspin expression in studied cells significantly correlated with cisplatin sensitivity. A significantly shorter overall survival and progression-free survival was associated with lower cytoplasmic maspin expression at first-look laparotomies and nuclear maspin expression and secondary cytoreductions. Higher nuclear maspin at first-look laparotomies expression was specific for cases of complete response. In the study, the elevated expression of maspin was shown to be typical for cisplatin-sensitive ovarian cancers. 相似文献
18.
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. 总被引:1,自引:0,他引:1
Emanuel F Petricoin Verena E Bichsel Valerie S Calvert Virginia Espina Mary Winters Lynn Young Claudio Belluco Bruce J Trock Marc Lippman David A Fishman Dennis C Sgroi Peter J Munson Laura J Esserman Lance A Liotta 《Journal of clinical oncology》2005,23(15):3614-3621
Mapping tumor cell protein networks in vivo will be critical for realizing the promise of patient-tailored molecular therapy. Cancer can be defined as a dysregulation or hyperactivity in the network of intracellular and extracellular signaling cascades. These protein signaling circuits are the ultimate targets of molecular therapy. Each patient's tumor may be driven by a distinct series of molecular pathogenic defects. Thus, for any single molecular targeted therapy, only a subset of cancer patients may respond. Individualization of therapy, which tailors a therapeutic regimen to a tumor molecular portrait, may be the solution to this dilemma. Until recently, the field lacked the technology for molecular profiling at the genomic and proteomic level. Emerging proteomic technology, used concomitantly with genomic analysis, promises to meet this need and bring to reality the clinical adoption of molecular stratification. The activation state of kinase-driven signal networks contains important information relative to cancer pathogenesis and therapeutic target selection. Proteomic technology offers a means to quantify the state of kinase pathways, and provides post-translational phosphorylation data not obtainable by gene arrays. Case studies using clinical research specimens are provided to show the feasibility of generating the critical information needed to individualize therapy. Such technology can reveal potential new pathway interconnections, including differences between primary and metastatic lesions. We provide a vision for individualized combinatorial therapy based on proteomic mapping of phosphorylation end points in clinical tissue material. 相似文献
19.
Francis Giles Srdan Verstovsek Deborah Thomas Stanton Gerson Jorge Cortes Stefan Faderl Alessandra Ferrajoli Farhad Ravandi Steven Kornblau Guillermo Garcia-Manero Elias Jabbour Susan O'Brien Verena Karsten Ann Cahill Karen Yee Maher Albitar Mario Sznol Hagop Kantarjian 《Clinical cancer research》2005,11(21):7817-7824
PURPOSE: Cloretazine (VNP40101M) is a novel sulfonylhydrazine alkylating agent with significant antileukemia activity. A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease. DESIGN: Ara-C was given i.v. at a fixed dose of 1.5 gm/m(2)/d by continuous infusion for 4 days (patients ages <65 years at time of diagnosis) or 3 days (patients ages > or =65 years). Cloretazine was given i.v. over 15 to 60 minutes on day 2 at a starting dose of 200 mg/m(2), with escalation in 100 mg/m(2) increments in cohorts of three to six patients until a maximum tolerated dose was established. The DNA repair enzyme O(6)-alkylguanine DNA alkyltransferase (AGT) was measured at baseline. RESULTS: Forty patients, including 32 with acute myeloid leukemia, received 47 courses of treatment. Complete responses were seen at cloretazine dose levels of > or =400 mg/m(2) in 10 of 37 (27%) evaluable patients, and in this patient subset, AGT activity was significantly lower in patients that responded to treatment than in patients who did not (P < or = 0.027). Dose-limiting toxicities (gastrointestinal and myelosuppression) were seen with 500 and 600 mg/m(2) of cloretazine combined with the 4-day ara-C schedule but not seen with the 3-day schedule. CONCLUSION: The recommended cloretazine dose schedule for future studies is 600 mg/m(2) combined with 1.5 gm/m(2)/d continuous infusion of ara-C for 3 days. The cloretazine and ara-C regimen has significant antileukemic activity. AGT activity may be a predictor of response to cloretazine. 相似文献
20.
Sorafenib and azacitidine as salvage therapy for relapse of FLT3‐ITD mutated AML after allo‐SCT
下载免费PDF全文
![点击此处可从《European journal of haematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)